Mark N. Prichard

7.0k total citations · 1 hit paper
143 papers, 5.4k citations indexed

About

Mark N. Prichard is a scholar working on Epidemiology, Genetics and Virology. According to data from OpenAlex, Mark N. Prichard has authored 143 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Epidemiology, 31 papers in Genetics and 30 papers in Virology. Recurrent topics in Mark N. Prichard's work include Herpesvirus Infections and Treatments (78 papers), Cytomegalovirus and herpesvirus research (74 papers) and Virus-based gene therapy research (31 papers). Mark N. Prichard is often cited by papers focused on Herpesvirus Infections and Treatments (78 papers), Cytomegalovirus and herpesvirus research (74 papers) and Virus-based gene therapy research (31 papers). Mark N. Prichard collaborates with scholars based in United States, Ukraine and United Kingdom. Mark N. Prichard's co-authors include Charles Shipman, Earl R. Kern, Caroll B. Hartline, Dana G. Wolf, Edward S. Mocarski, Emma A. Harden, C. Shipman, Kathy A. Keith, Scott H. James and Debra C. Quenelle and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Mark N. Prichard

141 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Host Immune System Gene Targeting by a Viral miRNA

2007 514 citations Mark N. Prichard et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark N. Prichard United States	39	3.5k	1.4k	1.1k	837	797	143	5.4k
Andrea Carfı́ United States	44	2.6k 0.8×	2.6k 1.9×	1.6k 1.4×	503 0.6×	762 1.0×	91	6.7k
Thomas Stamminger Germany	51	5.0k 1.5×	2.8k 2.0×	660 0.6×	700 0.8×	1.2k 1.5×	169	7.8k
Brett D. Lindenbach United States	40	4.7k 1.4×	2.7k 1.9×	2.5k 2.2×	926 1.1×	399 0.5×	71	10.5k
Arno Müllbacher Australia	50	1.6k 0.5×	1.8k 1.3×	1.9k 1.7×	558 0.7×	615 0.8×	177	7.1k
D. Lorne Tyrrell Canada	46	2.9k 0.8×	2.3k 1.6×	2.1k 1.9×	400 0.5×	413 0.5×	206	7.4k
Glenn Randall United States	36	2.4k 0.7×	2.6k 1.9×	1.2k 1.1×	667 0.8×	390 0.5×	66	6.9k
Hak Hotta Japan	44	2.9k 0.8×	1.9k 1.4×	805 0.7×	264 0.3×	413 0.5×	229	6.4k
Dominique Mazier France	57	1.8k 0.5×	1.9k 1.3×	1.0k 0.9×	504 0.6×	844 1.1×	265	9.9k
Jean Dubuisson France	71	8.5k 2.4×	3.1k 2.2×	2.2k 2.0×	1.6k 1.9×	473 0.6×	263	15.7k
Ju‐Tao Guo United States	53	5.3k 1.5×	1.8k 1.3×	2.4k 2.1×	793 0.9×	351 0.4×	120	8.3k

Countries citing papers authored by Mark N. Prichard

Since Specialization

Citations

This map shows the geographic impact of Mark N. Prichard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Prichard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Prichard more than expected).

Fields of papers citing papers by Mark N. Prichard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Prichard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Prichard. The network helps show where Mark N. Prichard may publish in the future.

Co-authorship network of co-authors of Mark N. Prichard

This figure shows the co-authorship network connecting the top 25 collaborators of Mark N. Prichard. A scholar is included among the top collaborators of Mark N. Prichard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark N. Prichard. Mark N. Prichard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shiraki, Kimiyasu, Tohru Daikoku, Mark N. Prichard, et al.. (2024). Vertical mother‐to‐infant transmission of herpes simplex virus 2 is correlated with tropism due to mutations in viral UL13. Journal of Medical Virology. 96(1). e29379–e29379. 1 indexed citations

Gardner, Thomas J., Steven M. Kwasny, Steven C. Cardinale, et al.. (2022). Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus. Antiviral Research. 209. 105474–105474. 3 indexed citations

King, Steven, Maureen Legendre, Michael D. Swanson, et al.. (2021). Targeted disruption of pi–pi stacking in Malaysian banana lectin reduces mitogenicity while preserving antiviral activity. Scientific Reports. 11(1). 656–656. 18 indexed citations

Xiao, Li, Amy E. Ratliff, Donna M. Crabb, et al.. (2020). Molecular Characterization of Mycoplasma pneumoniae Isolates in the United States from 2012 to 2018. Journal of Clinical Microbiology. 58(10). 34 indexed citations

Khusnutdinova, E. F., А. Н. Лобов, Anastasiya V. Petrova, et al.. (2020). Allobetulone rearrangement to l8αH,19βH-ursane triterpenoids with antiviral activity. Natural Product Research. 36(13). 1–11. 7 indexed citations

Akhtar, Lisa N., Daniel W. Renner, Utsav Pandey, et al.. (2019). Genotypic and Phenotypic Diversity of Herpes Simplex Virus 2 within the Infected Neonatal Population. mSphere. 4(1). 27 indexed citations

Camins, Bernard, et al.. (2019). Hospital-acquired viral respiratory infections in neonates hospitalized since birth in a tertiary neonatal intensive care unit. Journal of Perinatology. 39(5). 683–689. 10 indexed citations

Khusnutdinova, E. F., О. Б. Казакова, А. Н. Лобов, et al.. (2018). Synthesis of A-ring quinolones, nine-membered oxolactams and spiroindoles by oxidative transformations of 2,3-indolotriterpenoids. Organic & Biomolecular Chemistry. 17(3). 585–597. 26 indexed citations

Pécheur, Eve‐Isabelle, Viktoriya Borisevich, Peter Halfmann, et al.. (2016). The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. Journal of Virology. 90(6). 3086–3092. 127 indexed citations

10.

James, Scott H. & Mark N. Prichard. (2014). Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance. Current Opinion in Virology. 8. 54–61. 87 indexed citations

11.

Li, Chengwei, Debra C. Quenelle, Mark N. Prichard, John C. Drach, & Jiří Žemlička. (2012). Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir. Bioorganic & Medicinal Chemistry. 20(8). 2669–2674. 8 indexed citations

12.

Prichard, Mark N., et al.. (2011). The Genetic Basis of Human Cytomegalovirus Resistance and Current Trends in Antiviral Resistance Analysis. Infectious Disorders - Drug Targets. 11(5). 504–513. 16 indexed citations

13.

Valiaeva, Nadejda, Mark N. Prichard, R. Mark L. Buller, et al.. (2009). Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Research. 84(3). 254–259. 16 indexed citations

14.

Prichard, Mark N., Earl R. Kern, Debra C. Quenelle, et al.. (2008). Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine. Virology Journal. 5(1). 39–39. 11 indexed citations

15.

Quenelle, Debra C., et al.. (2008). Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. Antiviral Research. 80(2). 223–224. 10 indexed citations

16.

Kriesel, John D., Spotswood L. Spruance, Mark N. Prichard, Jacqueline N. Parker, & Earl R. Kern. (2005). Recurrent Antiviral‐Resistant Genital Herpes in an Immunocompetent Patient. The Journal of Infectious Diseases. 192(1). 156–161. 21 indexed citations

17.

Prichard, Mark N. & Earl R. Kern. (2005). Orthopoxvirus Targets for the Development of Antiviral Therapies. PubMed. 5(1). 17–28. 26 indexed citations

18.

Tugendreich, Stuart, Edward L. Perkins, Dongxu Sun, et al.. (2001). A Streamlined Process to Phenotypically Profile Heterologous cDNAs in Parallel Using Yeast Cell-Based Assays. Genome Research. 11(11). 1899–1912. 25 indexed citations

19.

Bilello, John A., et al.. (1995). Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid Glycoprotein. The Journal of Infectious Diseases. 171(3). 546–551. 47 indexed citations

20.

Prichard, Mark N., et al.. (1993). Inhibitors of thymidylate synthase and dihydrofolate reductase potentiate the antiviral effect of acyclovir. Antiviral Research. 20(3). 249–259. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact